BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 32321456)

  • 1. Tumor characteristics, treatments, and survival outcomes in prostate cancer patients with a PSA level < 4 ng/ml: a population-based study.
    Zheng Z; Zhou Z; Yan W; Zhou Y; Chen C; Li H; Ji Z
    BMC Cancer; 2020 Apr; 20(1):340. PubMed ID: 32321456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First postoperative PSA is associated with outcomes in patients with node positive prostate cancer: Results from the SEARCH database.
    McDonald ML; Howard LE; Aronson WJ; Terris MK; Cooperberg MR; Amling CL; Freedland SJ; Kane CJ
    Urol Oncol; 2018 May; 36(5):239.e17-239.e25. PubMed ID: 29429895
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early prostate-specific antigen relapse after radical retropubic prostatectomy: prediction on the basis of preoperative and postoperative tumor characteristics.
    Graefen M; Noldus J; Pichlmeier U; Haese A; Hammerer P; Fernandez S; Conrad S; Henke R; Huland E; Huland H
    Eur Urol; 1999; 36(1):21-30. PubMed ID: 10364651
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stage at presentation and survival outcomes of patients with Gleason 8-10 prostate cancer and low prostate-specific antigen.
    Falchook AD; Martin NE; Basak R; Smith AB; Milowsky MI; Chen RC
    Urol Oncol; 2016 Mar; 34(3):119.e19-26. PubMed ID: 26526383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age and PSA predict likelihood of organ-confined disease in men presenting with PSA less than 10 ng/mL: implications for screening.
    Aleman M; Karakiewicz PI; Kupelian P; Kattan MW; Graefen M; Cagiannos I; Eastham J; Scardino PT; Huland H; Klein EA
    Urology; 2003 Jul; 62(1):70-4. PubMed ID: 12837425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognosis of prostate cancer and bone metastasis pattern of patients: a SEER-based study and a local hospital based study from China.
    Liu D; Kuai Y; Zhu R; Zhou C; Tao Y; Han W; Chen Q
    Sci Rep; 2020 Jun; 10(1):9104. PubMed ID: 32499554
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The U Shape of Prostate-specific Antigen and Prostate Cancer-specific Mortality in High-grade Metastatic Prostate Adenocarcinoma.
    Wang J; Abudurexiti M; Shao N; Wei Y; Zhu Y; Ye DW
    Eur Urol Focus; 2020 Jan; 6(1):53-62. PubMed ID: 30217630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
    Eminaga O; Hinkelammert R; Titze U; Abbas M; Eltze E; Bettendorf O; Semjonow A
    Urol Oncol; 2014 Jan; 32(1):32.e17-25. PubMed ID: 23434425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcomes in patients with Gleason score 8-10 prostate cancer: relation to preoperative PSA level.
    McGuire BB; Helfand BT; Loeb S; Hu Q; O'Brien D; Cooper P; Yang X; Catalona WJ
    BJU Int; 2012 Jun; 109(12):1764-9. PubMed ID: 22017732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions.
    Nelson CP; Dunn RL; Wei JT; Rubin MA; Montie JE; Sanda MG
    Urol Oncol; 2003; 21(3):213-8. PubMed ID: 12810209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Men presenting with prostate-specific antigen (PSA) values of over 100 ng/mL.
    Ang M; Rajcic B; Foreman D; Moretti K; O'Callaghan ME
    BJU Int; 2016 Apr; 117 Suppl 4():68-75. PubMed ID: 26890320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical and pathological significance of the level and extent of capsular invasion in clinical stage T1-2 prostate cancer.
    Wheeler TM; Dillioglugil O; Kattan MW; Arakawa A; Soh S; Suyama K; Ohori M; Scardino PT
    Hum Pathol; 1998 Aug; 29(8):856-62. PubMed ID: 9712429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictive factors and the important role of detectable prostate-specific antigen for detection of clinical recurrence and cancer-specific mortality following robot-assisted radical prostatectomy.
    García-Barreras S; Rozet F; Nunes-Silva I; Srougi V; Sanchez-Salas R; Barret E; Galiano M; Cathelineau X
    Clin Transl Oncol; 2018 Aug; 20(8):1004-1010. PubMed ID: 29243074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extreme-risk prostate adenocarcinoma presenting with prostate-specific antigen (PSA)>40 ng/ml: prognostic significance of the preradiation PSA nadir.
    Alexander AS; Mydin A; Jones SO; Christie J; Lim JT; Truong PT; Ludgate CM
    Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e713-9. PubMed ID: 21277102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study.
    Culp SH; Schellhammer PF; Williams MB
    Eur Urol; 2014 Jun; 65(6):1058-66. PubMed ID: 24290503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of microvessel density in predicting recurrence in pathologic Stage T3 prostatic adenocarcinoma.
    Gettman MT; Pacelli A; Slezak J; Bergstralh EJ; Blute M; Zincke H; Bostwick DG
    Urology; 1999 Sep; 54(3):479-85. PubMed ID: 10475358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of preoperative butyrylcholinesterase as an independent predictor of biochemical recurrence-free survival in patients with prostate cancer treated with radical prostatectomy.
    Koie T; Ohyama C; Hatakeyama S; Imai A; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Hosogoe S; Yamamoto H; Kitayama M; Hirota K
    Int J Clin Oncol; 2016 Apr; 21(2):379-383. PubMed ID: 26223693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing PSA outcome after radical prostatectomy or magnetic resonance imaging-guided partial prostatic irradiation in select patients with clinically localized adenocarcinoma of the prostate.
    D'amico AV; Tempany CM; Schultz D; Cormack RA; Hurwitz M; Beard C; Albert M; Kooy H; Jolesz F; Richie JP
    Urology; 2003 Dec; 62(6):1063-7. PubMed ID: 14665356
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.